GlassScriptPhysician profile
Katherine E Branum
NPI 1306034087
$7,530.83
in general payments reported to CMS, 2019-2025
35 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,683 · 2022: $1,458 · 2023: $1,573 · 2024: $1,371 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,213.82 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,053.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $641.47 | 2021-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $583.14 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $511.31 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $392.96 | 2021-2024 | Xarelto |
| Glaxosmithkline, LLC. | $382.75 | 2021-2025 | Trelegy Ellipta |
| Astellas Pharma US INC | $350.71 | 2021-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.52 | 2022-2024 | Xifaxan, Trulance |
| Pfizer INC. | $229.55 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.61 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $200.98 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $186.71 | 2021-2025 | |
| Abbott Laboratories | $167.29 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $166.39 | 2024-2025 | Voquezna |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $149.62 | 2021-2025 | Eliquis |
| Abbvie INC. | $125.20 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $86.37 | 2022 | |
| Corium, LLC | $60.78 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $60.21 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $49.43 | 2025 | Gemtesa |
| Dexcom, INC. | $41.90 | 2021-2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $40.81 | 2025 | Inspire |
| Biohaven Pharmaceuticals, INC. | $36.53 | 2021 | |
| Sanofi Pasteur INC. | $33.94 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $21.09 | 2022 | |
| Hologic Sales and Service, LLC | $18.43 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.18 | 2025 | Rexulti |
| Medtronic, INC. | $16.02 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2024 | Livalo |
| Irhythm Technologies, INC. | $14.18 | 2023 | Zio Xt Patch |
| Averitas Pharma INC. | $14.17 | 2023 | Qutenza |
| Collegium Pharmaceutical, INC. | $14.10 | 2025 | Jornay Pm |
| Bioventus LLC | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Branum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.